![]() |
市場調查報告書
商品編碼
1896208
功能性腸道健康產品市場預測至2032年:按產品、成分、分銷管道、最終用戶和地區分類的全球分析Functional Gut Health Products Market Forecasts to 2032 - Global Analysis By Product (Dietary Supplements, Functional Foods, Functional Beverages and Other Products), Ingredient, Distribution Channel, End User and By Geography |
||||||
根據 Stratistics MRC 的一項研究,預計到 2025 年,全球功能性腸道健康產品市場價值將達到 91 億美元,到 2032 年將達到 173 億美元,預測期內複合年成長率為 9.5%。
功能性腸道健康產品是指旨在維持消化系統健康、促進營養吸收和增強腸道菌叢的膳食補充劑和食品/飲料。這些產品通常含有益生菌、益生元、後生元、膳食纖維或合益素,能有效平衡腸內菌叢、增強免疫功能和改善代謝功能。它們有助於預防消化系統疾病、減輕發炎並促進整體健康。消費者對腸道健康與免疫力、心理健康和慢性病管理之間關聯的認知不斷提高,推動了市場的發展。功能性腸道健康產品正擴大被添加到機能性食品、飲料和膳食補充劑中,這反映了預防醫學、個人化營養和以生活方式為導向的飲食干預日益成長的趨勢。
消費者對預防保健和健康產品的需求
在全球範圍內,人們對預防性醫療保健和健康的需求正在推動益生菌補充劑的普及。消費者對消化系統健康、免疫力和整體健康的日益關注,促使他們每天服用益生菌。機能性食品和補充劑擴大被作為綜合健康方案的一部分進行推廣。健康專家推薦益生菌作為傳統治療方法的輔助手段,進一步提升了其可信度。這種趨勢將消費者的健康需求與預防性營養聯繫起來,並持續為益生菌市場的成長奠定基礎。
高昂的研發成本和監管障礙阻礙了健康聲明的實施。
研發成本和監管壁壘限制了益生菌生產商的擴張。開發經臨床檢驗的菌株需要大量投資於測試和配方研發。監管機構對健康聲明製定了嚴格的指導方針,導致產品上市延遲和合規成本增加。由於資源有限,小規模公司在與成熟公司競爭時面臨重重障礙。儘管市場需求不斷成長,但這些限制因素仍阻礙創新和市場擴張。
將個人化營養與基於DNA的健康概念結合
個人化營養和基於DNA的健康管理正在提升消費者參與度和產品差異化。各公司正拓展其微生物組檢測套組線,並結合個人化訂製的益生菌配方。人工智慧驅動的平台能夠根據基因和生活方式數據提供個人化建議。膳食補充劑公司與數位健康Start-Ups之間的合作正在加速創新。這項機會正在為益生菌領域創造新的收入來源,並增強消費者忠誠度。
保存期限穩定性和低溫運輸要求
保存期限穩定性及低溫運輸要求限制了益生菌產品的分銷和價格承受能力。活性益生菌菌株需要受控的儲存條件才能維持其功效。新興市場基礎設施不足限制了產品的供應和穩定性。高昂的物流成本使其與傳統膳食補充劑相比競爭力不足。這些挑戰持續阻礙益生菌產品的全球推廣和長期普及。
新冠感染疾病加速了益生菌的需求,因為消費者更加重視免疫力和預防性保健。疫情推動了已開發市場和新興市場對益生菌補充劑的廣泛應用。雖然封鎖措施擾亂了供應鏈和分銷,但線上通路的快速成長彌補了這一缺口。各大品牌利用以增強免疫力為重點的行銷策略,將益生菌定位為必需的健康產品。疫情後的復甦促進了零售和電商結合的混合分銷模式的出現。這種影響持續重塑消費者的行為,並強化了益生菌在預防性保健中的作用。
預計在預測期內,膳食補充劑細分市場將佔據最大的市場佔有率。
由於消費者對便捷的日常益生菌攝取需求不斷成長,預計膳食補充劑領域在預測期內將佔據最大的市場佔有率。膳食補充劑推動了益生菌膠囊、片劑和粉末等多種形式的普及。消費者青睞膳食補充劑,因為它們便於攜帶、劑量精準且易於融入日常生活。健康專家也擴大推薦膳食補充劑來促進消化器官系統和免疫健康。零售店和線上管道的廣泛普及進一步推動了膳食補充劑的銷售。憑藉其便捷的購買管道和廣泛的消費者群體,該領域將繼續保持主導地位。
預計在預測期內,芽孢桿菌細分市場將呈現最高的複合年成長率。
由於其穩定性和多功能性,芽孢桿菌細分市場預計將在預測期內實現最高成長率。芽孢桿菌菌株正在推動益生菌製劑在膳食補充劑和機能性食品領域的成長。與其他菌株不同,芽孢桿菌能夠耐受嚴苛的加工和儲存條件,從而降低對低溫運輸的依賴。其孢子形成特性延長了保存期限,增強了其全球分銷潛力。對芽孢桿菌改善腸道環境和免疫功能功效的研究不斷深入,正在加速其應用。由於其可擴展性和韌性,預計該細分市場將超越其他細分市場。
在預測期內,北美地區預計將佔據最大的市場佔有率,這主要得益於其先進的基礎設施和較高的消費者意識。對預防性保健和機能性食品的強勁需求正在推動益生菌的普及。領先的營養保健品公司正在加大研發投入並拓展產品系列。監管環境的明朗化和消費者可支配收入的提高正在推動市場成熟。電子商務的興起和健康意識行銷的普及正在加速益生菌的推廣。北美地區將繼續在收入和創新方面保持領先地位。
預計亞太地區在預測期內將實現最高的複合年成長率,這主要得益於快速的都市化和日益增強的健康意識。中國、日本、印度和東南亞的強勁需求正在推動益生菌市場的成長。本土Start-Ups公司和全球公司正在拓展價格親民且符合當地文化習慣的益生菌產品。中產階級收入的成長和數位技術的廣泛應用正在加速市場滲透。政府對預防性醫療保健和營養的支持正在推動益生菌市場的長期成長。
According to Stratistics MRC, the Global Functional Gut Health Products Market is accounted for $9.1 billion in 2025 and is expected to reach $17.3 billion by 2032 growing at a CAGR of 9.5% during the forecast period. Functional gut health products are dietary supplements, foods, and beverages designed to support digestive health, enhance nutrient absorption, and strengthen the gut microbiome. These products typically contain probiotics, prebiotics, postbiotics, dietary fibers, or synbiotics that improve intestinal flora balance, immunity, and metabolic function. They help prevent digestive disorders, reduce inflammation, and contribute to overall wellness. Rising consumer awareness of gut health's link to immunity, mental health, and chronic disease management drives the market. Functional gut health products are increasingly integrated into functional foods, beverages, and nutraceuticals, reflecting a growing trend toward preventive healthcare, personalized nutrition, and lifestyle-focused dietary interventions.
Consumer demand for preventive healthcare and wellness products
Preventive healthcare and wellness demand is boosting adoption of probiotic supplements globally. Rising awareness of digestive health, immunity, and overall well-being is propelling consumers toward daily probiotic intake. Functional foods and supplements are increasingly marketed as part of holistic wellness routines. Healthcare professionals are recommending probiotics as adjuncts to conventional treatments, further strengthening credibility. This driver continues to anchor growth by aligning consumer health priorities with preventive nutrition.
High R&D costs and regulatory hurdles for health claims
R&D costs and regulatory hurdles are limiting scalability for probiotic manufacturers. Developing clinically validated strains requires significant investment in trials and formulation. Regulatory bodies impose strict guidelines on health claims, delaying product launches and increasing compliance costs. Smaller companies face barriers in competing with established players due to limited resources. This restraint continues to constrain innovation and market expansion despite rising demand.
Integration with personalized nutrition and DNA-based wellness
Personalized nutrition and DNA-based wellness are enhancing consumer engagement and product differentiation. Companies are increasingly offering microbiome testing kits linked to tailored probiotic formulations. AI-driven platforms are enabling personalized recommendations based on genetic and lifestyle data. Partnerships between nutraceutical firms and digital health startups are accelerating innovation. This opportunity is unlocking new revenue streams and strengthening consumer loyalty in the probiotic sector.
Shelf-life stability and cold-chain requirements
Shelf-life stability and cold-chain requirements are constraining distribution and affordability. Live probiotic strains require controlled storage conditions to maintain efficacy. Inadequate infrastructure in emerging markets limits product availability and consistency. High logistics costs reduce competitiveness compared to conventional supplements. This threat continues to challenge global expansion and long-term adoption of probiotics.
Covid-19 accelerated demand for probiotics as consumers prioritized immunity and preventive health. Covid-19 boosted probiotic supplement adoption across both developed and emerging markets. Lockdowns disrupted supply chains and distribution, but online channels compensated with rapid growth. Brands leveraged immunity-focused marketing to position probiotics as essential wellness products. Post-pandemic recovery is fostering hybrid distribution models combining retail and e-commerce. This impact continues to reshape consumer behavior and strengthen probiotics' role in preventive healthcare.
The dietary supplements segment is expected to be the largest during the forecast period
The dietary supplements segment is expected to account for the largest market share during the forecast period owing to rising demand for convenient, daily probiotic intake. Dietary supplements are driving adoption of probiotics across capsules, tablets, and powders. Consumers favor supplements for their portability, dosage accuracy, and ease of integration into routines. Healthcare professionals increasingly recommend supplements for digestive and immune health. Expanding retail and online availability is accelerating adoption. This segment continues to dominate due to its accessibility and broad consumer appeal.
The bacillus segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the bacillus segment is predicted to witness the highest growth rate due to its stability and versatility. Bacillus strains are driving growth in probiotic formulations across supplements and functional foods. Unlike other strains, bacillus can withstand harsh processing and storage conditions, reducing cold-chain dependency. Their spore-forming nature enhances shelf-life and global distribution potential. Rising research on bacillus efficacy in gut health and immunity is accelerating adoption. This segment is expected to outpace others due to its scalability and resilience.
During the forecast period, the North America region is expected to hold the largest market share due to advanced infrastructure and high consumer awareness. North America is driving probiotic adoption through strong demand for preventive healthcare and functional foods. Leading nutraceutical companies are investing in R&D and expanding product portfolios. Regulatory clarity and high disposable incomes are fostering market maturity. E-commerce penetration and wellness-focused marketing are accelerating adoption. North America continues to dominate in both revenue and innovation leadership.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR owing to rapid urbanization and rising health consciousness. Asia Pacific is driving probiotic growth through strong demand in China, Japan, India, and Southeast Asia. Local startups and global players are scaling affordable and culturally tailored probiotic products. Rising middle-class incomes and digital adoption are accelerating market penetration. Government support for preventive healthcare and nutrition is fostering long-term growth.
Key players in the market
Some of the key players in Functional Gut Health Products Market include Nestle Health Science, Danone S.A., Chr. Hansen Holding A/S, DuPont de Nemours Inc., Kerry Group plc, Yakult Honsha Co. Ltd., Amway Corporation, Bayer AG, BioGaia AB, DSM-Firmenich AG, Probi AB, Arla Foods amba, General Mills Inc., NOW Foods and Garden of Life LLC.
In June 2025, Danone acquired The Akkermansia Company (TAC), a Belgian biotech pioneer specializing in next-generation biotics, for approximately $200 million. TAC's patented strain Akkermansia muciniphila MucT(TM) has been clinically validated to support gut barrier function, reduce inflammation, and address metabolic disorders such as obesity and diabetes.
In April 2024, Nestle India and Dr. Reddy's Laboratories formed a joint venture to bring nutraceutical and probiotic brands to consumers across India and agreed territories. This collaboration strengthens Nestle's presence in gut health by combining its global nutrition expertise with Dr. Reddy's pharmaceutical distribution network.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.